Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. Cascadian Therapeutics' clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. Cascadian Therapeutics completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Show more
Type
Subsidiary
Parent Company
Seattle Genetics
HQ
Seattle, US
Founded
2007
Cascadian Therapeutics was founded in 2007 and is headquartered in Seattle, US
Report incorrect company information

Key People/Management at Cascadian Therapeutics

Scott Myers

Scott Myers

President, Chief Executive Officer and Director
PE Gary W. Christianson

PE Gary W. Christianson

Chief Operating Officer
Scott Peterson

Scott Peterson

Chief Scientific Officer
Luke Walker

Luke Walker

Senior Vice President, Clinical Development
Monique Greer

Monique Greer

Senior Vice President, Investor Relations and Corporate Communications
Julie Eastland

Julie Eastland

Chief Financial Officer and Chief Business Officer
Show more

Cascadian Therapeutics Office Locations

Cascadian Therapeutics has an office in Seattle
Seattle, US (HQ)
500 2601 4th Ave
Show all (1)
Report incorrect company information

Cascadian Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2007
Cascadian Therapeutics is a subsidiary of Seattle Genetics

Cascadian Therapeutics Financials

Annual
USDFY, 2016FY, 2017

General and administrative expense

17.6 m14.1 m

R&D expense

27.5 m44 m

Operating expense total

45.1 m58.1 m

EBIT

(64.8 m)(58.1 m)
Quarterly
USDQ3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

General and administrative expense

2.1 m2.3 m2.4 m2.3 m2.6 m2.1 m6.6 m4.4 m3.5 m3 m3.5 m

R&D expense

5.5 m4.8 m5.7 m5.8 m5.7 m5.1 m6.3 m6.4 m7.3 m8.6 m11.5 m

Operating expense total

7.6 m7.2 m8 m8.1 m8.3 m7.2 m13 m30.5 m10.8 m11.6 m15 m

EBIT

(7.6 m)(7.2 m)(8 m)(8.1 m)(8.3 m)(7.2 m)(13 m)(30.5 m)(10.8 m)(11.6 m)(15 m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

9.3 m10.5 m27.9 m13.7 m16.8 m

Accounts Receivable

Inventories

Current Assets

60.9 m58.9 m58 m64.5 m94.8 m
Quarterly
USDQ3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

12.8 m6.3 m34.2 m13.5 m12.9 m25.3 m13.9 m51 m16.6 m35.7 m12.9 m

Current Assets

64.1 m59.6 m82 m75 m70.8 m64.4 m48.2 m81.8 m73.1 m127.8 m123.9 m

PP&E

1.8 m1.7 m1.7 m1.9 m1.8 m1.9 m1.7 m1.6 m1.3 m1.7 m1.5 m

Goodwill

2.1 m2.1 m16.7 m16.7 m16.7 m16.7 m16.7 m16.7 m16.7 m16.7 m16.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(38.8 m)(50 m)(32.6 m)(57.7 m)(56.9 m)

Depreciation and Amortization

489 k512 k613 k642 k956 k

Inventories

Accounts Payable

(600 k)144 k(250 k)385 k1.4 m
Quarterly
USDQ3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7.7 m)(9.6 m)(6.7 m)(7.9 m)(10.9 m)(4.6 m)(12.9 m)(23.5 m)(10.8 m)(11.4 m)

Accounts Payable

303 k497 k353 k389 k832 k1.3 m741 k1 m
Show all financial metrics

Cascadian Therapeutics Operating Metrics

FY, 2016

Patents (US)

1

Patents (foreign)

18

Patents Licensed

222
Show all operating metrics
Report incorrect company information